Making custom CRISPR therapies could be harder than initially thoughtnews2026-04-01T19:40:47+00:00April 1st, 2026|Endpoints News|
FDA delays decision on Orca Bio cell therapy after filing more manufacturing datanews2026-04-01T12:00:29+00:00April 1st, 2026|Endpoints News|
Astellas doesn’t pick up AviadoBio’s gene therapy, but nonprofit funding will move it forwardnews2026-03-31T15:33:37+00:00March 31st, 2026|Endpoints News|
First clinical trial of tRNA therapy will start soonnews2026-03-31T11:00:50+00:00March 31st, 2026|Endpoints News|
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibodynews2026-03-28T21:24:57+00:00March 28th, 2026|Endpoints News|
FDA approves Rocket’s gene therapy for ultra-rare immune diseasenews2026-03-27T15:13:30+00:00March 27th, 2026|Endpoints News|
AstraZeneca’s in vivo CAR-T led to early responses, but one death in China trialnews2026-03-27T12:00:35+00:00March 27th, 2026|Endpoints News|
After tumultuous year, Sarepta plots rebound with early data on RNA therapiesnews2026-03-25T15:41:06+00:00March 25th, 2026|Endpoints News|
Ocugen heads to Phase 3 with gene therapy for geographic atrophynews2026-03-24T15:40:16+00:00March 24th, 2026|Endpoints News|
Q&A: Controversial embryo editing entrepreneur Cathy Tie on her new startupnews2026-03-24T14:10:54+00:00March 24th, 2026|Endpoints News|
